Nothing but negotiation

The Gap Partnership

CytoDyn acquires Pro 140 from Progenics

Progenics has sold Pro 140 to CytoDyn.

18 October 2012

CytoDyn has been in contract negotiations with Progenics Pharmaceuticals and has purchased its experimental humanised monoclonal antibody Pro 140.

The overall purchase price of this deal was $3.5 million and this will see the transfer of the technology to CytoDyn from Progenics, as well as the sale of all associated property and approximately 25 million mgs of the drug.

There will be further payments of $1.5 million when a clinical trial commences, while $5 million will be paid when the new treatment is approved.

Progenics is also to receive five per cent royalty payments when the medicine becomes commercially available.

CytoDyn is focused on the development of treatments for immune deficiency disorders and the biotechnology company's interim president and chief executive officer Dr Nader Pourhassan said: "Pro 140 is the most advanced cell-specific monoclonal antibody to date being tested for the treatment of HIV."

"We are excited about taking it forward through the next stages of clinical development," he added.

Posted by Ron Maverick

Source: CytoDyn press release, October 17th

Gap News

March 2014

The Negotiation Roadshow 2014

Generating value through creative negotiation

Read more

July 2013

Trading Global: Negotiating in the Far East

The Gap Partnership are hosting a complimentary Lunch & Learn seminar in association with UK Trade & Investment

Read more

April 2013

GroceryAid Negotiation Event Raises £26,550

The Gap Partnership, in conjunction with Asda, SC Johnson and Waitrose, host one-day negotiation workshop

Read more

February 2013

Trading Global - Negotiating in the Far East

What is the impact of cultural differences on your negotiations?

Read more

December 2012

The Gap Partnership Release New Negotiation Video

The Nothing but Negotiation video series continues with collaborative negotiation

Read more